BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10691826)

  • 1. Rising incidence of prostate cancer in Scotland: increased risk or increased detection?
    Brewster DH; Fraser LA; Harris V; Black RJ
    BJU Int; 2000 Mar; 85(4):463-72; discussion 472-3. PubMed ID: 10691826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of increasing detection in the rising incidence of prostate cancer.
    Potosky AL; Miller BA; Albertsen PC; Kramer BS
    JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate.
    Merrill RM; Wiggins CL
    Urol Oncol; 2002; 7(5):213-9. PubMed ID: 12644219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Prostate Specific Antigen (PSA) testing and prostate cancer incidence and mortality in Australia: A critical analysis.
    Pathirana T; Sequeira R; Del Mar C; Dickinson JA; Armstrong BK; Bell KJL; Glasziou P
    Cancer Epidemiol; 2022 Apr; 77():102093. PubMed ID: 35026706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer trends in Canada: rising incidence or increased detection?
    Levy IG; Gibbons L; Collins JP; Perkins DG; Mao Y
    CMAJ; 1993 Sep; 149(5):617-24. PubMed ID: 8364818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates.
    Merrill RM; Feuer EJ; Warren JL; Schussler N; Stephenson RA
    Am J Epidemiol; 1999 Oct; 150(8):848-60. PubMed ID: 10522656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer and prostate-specific antigen testing in New South Wales.
    Smith DP; Supramaniam R; Marshall VR; Armstrong BK
    Med J Aust; 2008 Sep; 189(6):315-8. PubMed ID: 18803534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geospatial and temporal variation of prostate cancer incidence.
    Wah W; Ahern S; Evans S; Millar J; Evans M; Earnest A
    Public Health; 2021 Jan; 190():7-15. PubMed ID: 33321358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.
    Legler JM; Feuer EJ; Potosky AL; Merrill RM; Kramer BS
    Cancer Causes Control; 1998 Oct; 9(5):519-27. PubMed ID: 9934717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study.
    Morgan RM; Steele RJ; Nabi G; McCowan C
    J Urol; 2013 Oct; 190(4):1207-12. PubMed ID: 23608675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India.
    Varghese J; Kuruvilla PM; Mehta N; Rathore RS; Babu M; Bansal D; Pillai B; Sam MP; Krishnamorthy H
    Asian Pac J Cancer Prev; 2016; 17(4):2255-8. PubMed ID: 27221926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
    Jones JS; Follis HW; Johnson JR
    Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disappearance of well-differentiated carcinoma of the prostate: effect of transurethral resection of the prostate, prostate-specific antigen, and prostate biopsy.
    Endrizzi J; Optenberg S; Byers R; Thompson IM
    Urology; 2001 Apr; 57(4):733-6. PubMed ID: 11306392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen testing for prostate cancer: Depleting a limited pool of susceptible individuals?
    Valberg M; Grotmol T; Tretli S; Veierød MB; Moger TA; Devesa SS; Aalen OO
    Eur J Epidemiol; 2017 Jun; 32(6):511-520. PubMed ID: 27431530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
    Tonita JM; Skarsgard D; Muhajarine N
    Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discrepancies between guidelines and clinical practice regarding prostate-specific antigen testing.
    Hamoen EH; Reukers DF; Numans ME; Barentsz JO; Witjes JA; Rovers MM
    Fam Pract; 2013 Dec; 30(6):648-54. PubMed ID: 24107269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
    Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
    Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening in the Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur J Cancer; 2000 Jun; 36(10):1322-35. PubMed ID: 10882875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent trends in prostate cancer incidence and mortality in southeast England.
    Evans HS; Møller H
    Eur Urol; 2003 Apr; 43(4):337-41. PubMed ID: 12667713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.